EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) Stock News

Canada - TSX:EPRX - CA29842P1053 - Common Stock

9.39 CAD

+0.09 (+0.97%)

Last: 11/17/2025, 7:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

EPRX.CA Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX

Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

14 days ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

2 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

2 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX

Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option

2 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX

Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares

7 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX

News Image

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

2 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX

Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares

3 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX

First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI

3 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

4 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

6 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

6 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

7 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results